Streetbeat News

Analyst Ratings

BNTX

HC Wainwright & Co. has reiterated its Buy rating for BioNTech (NASDAQ:BNTX) and maintained a price target of $113, as stated by analyst Robert Burns.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:30 am

ENLC

Morgan Stanley has downgraded EnLink Midstream (NYSE:ENLC) from Overweight to Equal-Weight, while maintaining the price target at $16.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:29 am

IOBT

HC Wainwright & Co. has reiterated its Buy rating on IO Biotech, maintaining a price target of $12. This indicates continued confidence in the company's potential growth and performance.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:27 am

KMI

Morgan Stanley has upgraded Kinder Morgan (NYSE:KMI) from Underweight to Equal-Weight, maintaining the price target at $24.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:26 am

OKE

Morgan Stanley has upgraded ONEOK (NYSE:OKE) from Equal-Weight to Overweight, with a new price target of $111, up from $103.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:23 am

ALLY

Keefe, Bruyette & Woods has maintained an 'Outperform' rating on Ally Financial but lowered the price target from $50 to $44, indicating a more cautious outlook.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:18 am

ACRV

HC Wainwright & Co. has reiterated its Buy rating for Acrivon Therapeutics, maintaining a price target of $22. Analyst Emily Bodnar continues to support the company's potential.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:18 am

MTN

Deutsche Bank analyst Chris Woronka maintains a Hold rating on Vail Resorts (NYSE:MTN) and lowers the price target from $218 to $194.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:15 am

RLAY

HC Wainwright & Co. has maintained a Buy rating on Relay Therapeutics and increased the price target from $18 to $19, indicating positive sentiment from the analyst.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:14 am

PRLD

HC Wainwright & Co. has reiterated a Neutral rating for Prelude Therapeutics with a maintained price target of $5.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:07 am